DOP2024000049A - Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos - Google Patents

Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos

Info

Publication number
DOP2024000049A
DOP2024000049A DO2024000049A DO2024000049A DOP2024000049A DO P2024000049 A DOP2024000049 A DO P2024000049A DO 2024000049 A DO2024000049 A DO 2024000049A DO 2024000049 A DO2024000049 A DO 2024000049A DO P2024000049 A DOP2024000049 A DO P2024000049A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
monocarboxylate transporter
human
mct1
human monocarboxylate
Prior art date
Application number
DO2024000049A
Other languages
English (en)
Spanish (es)
Inventor
Vladimirovna Rubtsova Kira
Charles Dorsey Frank
Benjamin Granger Joseph
Schroeder Oliver
Wang Wei
Original Assignee
Immunometabolism Dev Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunometabolism Dev Company Llc filed Critical Immunometabolism Dev Company Llc
Publication of DOP2024000049A publication Critical patent/DOP2024000049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DO2024000049A 2021-09-14 2024-03-12 Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos DOP2024000049A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US202163272903P 2021-10-28 2021-10-28
PCT/US2022/076400 WO2023044325A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DOP2024000049A true DOP2024000049A (es) 2024-06-16

Family

ID=83558178

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2024000049A DOP2024000049A (es) 2021-09-14 2024-03-12 Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos

Country Status (16)

Country Link
US (1) US11987624B2 (enExample)
EP (1) EP4402172A1 (enExample)
JP (2) JP7753348B2 (enExample)
KR (1) KR20240053656A (enExample)
AU (1) AU2022347031B2 (enExample)
CA (1) CA3230072A1 (enExample)
CL (1) CL2024000733A1 (enExample)
CO (1) CO2024003042A2 (enExample)
CR (1) CR20240133A (enExample)
DO (1) DOP2024000049A (enExample)
EC (1) ECSP24020235A (enExample)
IL (1) IL311253A (enExample)
JO (1) JOP20240054A1 (enExample)
MX (1) MX2024003115A (enExample)
TW (1) TWI842088B (enExample)
WO (1) WO2023044325A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087259A1 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
WO2012178173A1 (en) 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method
CA3087259A1 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Also Published As

Publication number Publication date
TWI842088B (zh) 2024-05-11
KR20240053656A (ko) 2024-04-24
WO2023044325A1 (en) 2023-03-23
CR20240133A (es) 2024-05-06
MX2024003115A (es) 2024-06-19
CL2024000733A1 (es) 2024-08-30
IL311253A (en) 2024-05-01
JP7753348B2 (ja) 2025-10-14
AU2022347031B2 (en) 2026-07-23
TW202330602A (zh) 2023-08-01
CA3230072A1 (en) 2023-03-23
JP2026004435A (ja) 2026-01-14
WO2023044325A9 (en) 2024-04-25
ECSP24020235A (es) 2024-06-28
CO2024003042A2 (es) 2024-03-18
JOP20240054A1 (ar) 2024-03-13
JP2023542639A (ja) 2023-10-11
US20230111363A1 (en) 2023-04-13
AU2022347031A1 (en) 2024-03-14
US11987624B2 (en) 2024-05-21
EP4402172A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
MX2021015518A (es) Anticuerpos que se unen a cd39 y sus usos.
CO2019010943A2 (es) Anticuerpos de unión a vista a ph ácido
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202092202A1 (ru) Конструкции антител к ror
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CL2024001304A1 (es) Anticuerpos anti-cd19 humano
CL2025002941A1 (es) Anticuerpos anti-sirp-alfa.
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2020009296A (es) Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
CL2022002520A1 (es) Anticuerpos anti-sea de muc1
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
ECSP24020235A (es) Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2022006941A (es) Epítopos de y anticuerpos contra trpv1.
ECSP22004680A (es) Anticuerpos anti-angpt2
MX2023009007A (es) Antagonistas de gitr y metodos de uso de los mismos.
CL2025000695A1 (es) Anticuerpos anti-lair1 humano
EA202290101A1 (ru) Антитела к angpt2
AR123050A1 (es) ANTICUERPOS ANTI-Ab